Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026

Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026

Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026

Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026

Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026

Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Multidrug Combo Testing Feasible in NSCLC

Cancer Discovery

|March 10, 2021

Summary

This summary is machine-generated.

The phase II HUDSON trial showed it is feasible to test many immunotherapy combinations at once for non-small cell lung cancer. This innovative trial design efficiently matches patients to treatments using biomarkers.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Nov 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Area of Science:

Oncology
Clinical Trials
Immunotherapy

Background:

Non-small cell lung cancer (NSCLC) treatment often involves complex immunotherapy regimens.
Testing multiple immunotherapy combinations simultaneously presents logistical and ethical challenges.

Discussion:

The phase II HUDSON trial investigated the feasibility of simultaneously testing multiple immunotherapy-based combinations in NSCLC patients.
Biomarker-driven treatment matching was incorporated where feasible to optimize patient selection.

Key Insights:

The HUDSON trial successfully demonstrated the feasibility of its novel, adaptive trial design.
Simultaneous testing of immunotherapy combinations can be efficiently managed within a structured clinical trial framework.

Outlook:

This study serves as a model for improving the efficiency of drug development and testing in oncology.
Future clinical trials can adopt similar adaptive designs to accelerate the evaluation of novel cancer therapies.